Biosimilars Clinical Supply Drug Development 
Drug Target Review
SEPTEMBER 10, 2024
The current landscape of protein drug development is characterised by accelerated timelines where new drugs are approved in months rather than years. In recent years, the biopharmaceutical industry has identified rapid Toxicology (Tox) material supply as the new critical path to IND readiness.
The Pharma Data
OCTOBER 27, 2020
The collaboration aims to leverage Molecular Partners’ proprietary DARPin® technologies and Novartis’ broad expertise in global drug development, regulatory affairs, manufacturing and commercialization to rapidly advance the program in keeping with the unprecedented global urgency created by the pandemic.
Expert insights. Personalized for you.
64 
Let's personalize your content